Parkinson Hastalığı Tedavisinde Apomorfin

Apomorfin, Parkinson hastalığı seyrinde görülen bazı motor ve non-motor komplikasyonların tedavisinde kullanılan, intermitan ya da sürekli infüzyon şeklinde uygulanabilen bir dopamin agonistidir. Apomorfin tedavisinin, motor dalgalanmalar ve diskineziler üzerine etkisi gösterilmiş olmasına rağmen, apomorfin testi ya da infüzyon uygulamaları ve tedavinin yönetimi ile ilgili yeterli fikir birliği yoktur. Bu derlemede amacımız, klinik pratikte apomorfinin kullanımı ile ilgili önerilerin yer aldığı “tedavi yönetim rehberi” oluşturmak ve gerek intermitan gerekse de sürekli infüzyon uygulamalarında karşılaşılan sorunları literatür bilgileri eşliğinde tartışmaktır.

Anahtar Kelime:

Apomorphine in the Treatment of Parkinson’s Disease

Öz:

Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson’s disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a “treatment management guideline,” which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Kim HJ, Mason S, Foltynie T, et al. Motor complications in Parkinson’s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 2020;35:185-190.
2. Aradi SD, Hauser RA. Medical management and prevention of motor complications in Parkinson’s disease. Neurotherapeutics 2020;17:1339- 1365.
3. Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord 2016;33(Suppl 1):S13-S21.
4. Trenkwalder C, Chaudhuri KR, García Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease--Clinical practice recommendations. Parkinsonism Relat Disord 2015;21:1023-1030.
5. Auffret M, Drapier S, Vérin M. The Many Faces of Apomorphine: Lessons from the past and challenges for the future. Drugs R D 2018;18:91-107.
6. Gee S. On the action of a new organic base, apomorphia. Clin Soc Trans 1869;2:166-169.
7. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 1951;56:251-253.
8. Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970;282:31-33.
9. Cotzias GC, Mena I, Papavasiliou PS, Mendez J. Unexpected findings with apomorphine and their possible consequences. Adv Neurol 1974;5:295-299.
10. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979;1:954-956.
11. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-406.
12. Kreczy-Kleedorfer B, Wagner M, Bösch S, Poewe W. Apomorphinpumpentherapie bei Patienten mit fortgeschrittener Parkinson- Krankheit [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease]. Nervenarzt 1993;64:221-225.
13. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
14. Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebocontrolled, crossover study. Arch Neurol 2008;65:193-198.
15. Pahwa R, Koller WC, Trosch RM, Sherry JH; APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-143.
16. Borgemeester RW, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord 2016;23:17-22.
17. Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord 2008;14:85-92.
18. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136.
19. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebocontrolled trial. Lancet Neurol 2018;17:749-759.
20. Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord 2019;34:353-365.
21. Food and Drug Administration, FDA Approved Labeling Text for NDA 021264. http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2010/021264s009lbl.pdf .
22. PharmaPendium, Post-marketing reports (AERS) for apomorphine hydrochloride and cardiac disorders https://www.pharmapendium. com/postmarket.do? initial. drug %5B0 %5D= Apomorphine +Hydrochloride&structure=false&multiView.statEntityType=EFFECT &chemistry=false&initial.effect%5B0%5D=Cardiac+disorders& multiView.entityType=DRUG.Bernstein RM. Reversible haemolytic anaemia after levodopa-carbidopa. Br Med J 1979;1:1461-1462.
23. Venegas Pérez B, Arquero Portero T, Sánchez Fernández MS, et al. Apomorphine-Induced Immune Hemolytic Anemia. Mov Disord Clin Pract 2016;4:145-147.
24. Hajiakhoundi F, Motamed M, Rohani M, Shahidi G. Apomorphine induced hemolytic anemia: A case report and literature review. Mov Disord 2019;340 (suppl 2).
25. European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommends restricting use of domperidone. EMA/129231/2014. https://www.ema.europa.eu/en/documents/referral/ prac-recommends-restricting-use-domperidone_en.pdf
26. Song BG, Lee YC, Min YW, et al. Risk of domperidone induced severe ventricular arrhythmia. Sci Rep 2020;10:12158.
27. Hughes AJ. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis. Adv Neurol 1999;80:363-368.
28. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
29. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term followup study of 64 patients. Mov Disord 2002;17:1235-1241.
30. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson’s disease. Drugs Aging 2004;21:687-709.
31. Poltawski L, Edwards H, Todd A, et al. Cutaneous side effects of infused apomorphine: the patient and carer experience. Br J Neurosci Nurs 2008;4:576-580.
32. Poltawski L, Edwards H, Todd A, et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009;24:115-118.
33. Sánchez AG, Andrade EL, Marsal JV, et al. A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients. Int J Neurosci 2017;127:404-411.
34. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.
35. Napier TC, Kirby A, Persons AL. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2020;102:109942.
36. Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord 2017;45:33-38.
37. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-270.
38. Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)- like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002;303:805-814.
39. Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997;3:103-107.
40. Kimber TE, Fang J, Huddy LJ, Thompson PD. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J 2017;47:570-573.
41. Tyne HL, Parsons J, Sinnott A, et al. A 10 year retrospective audit of longterm apomorphine use in Parkinson’s disease. J Neurol 2004;251:1370- 1374.
42. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007;22:2141-8; quiz 2295.
43. Bhidayasiri R, Boonpang K, Jitkritsadakul O, et al. Understanding the role of the Parkinson’s disease nurse specialist in the delivery of apomorphine therpy. Parkinsonism Relat Disord 2016;33 Suppl 1:S49-S55.

APA	Ozkan S, Erer S, Elibol B, Özkaynak S, çakmur r, Akbostanci M, Hanagasi H, DOGU O (2021). Parkinson Hastalığı Tedavisinde Apomorfin. , 358 - 365. 10.4274/tnd.2021.06706
Chicago	Ozkan Serhat,Erer Sevda,Elibol Bulent,Özkaynak Sehür Sibel,çakmur raif,Akbostanci Muhittin Cenk,Hanagasi Hasmet,DOGU OKAN Parkinson Hastalığı Tedavisinde Apomorfin. (2021): 358 - 365. 10.4274/tnd.2021.06706
MLA	Ozkan Serhat,Erer Sevda,Elibol Bulent,Özkaynak Sehür Sibel,çakmur raif,Akbostanci Muhittin Cenk,Hanagasi Hasmet,DOGU OKAN Parkinson Hastalığı Tedavisinde Apomorfin. , 2021, ss.358 - 365. 10.4274/tnd.2021.06706
AMA	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O Parkinson Hastalığı Tedavisinde Apomorfin. . 2021; 358 - 365. 10.4274/tnd.2021.06706
Vancouver	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O Parkinson Hastalığı Tedavisinde Apomorfin. . 2021; 358 - 365. 10.4274/tnd.2021.06706
IEEE	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O "Parkinson Hastalığı Tedavisinde Apomorfin." , ss.358 - 365, 2021. 10.4274/tnd.2021.06706
ISNAD	Ozkan, Serhat vd. "Parkinson Hastalığı Tedavisinde Apomorfin". (2021), 358-365. https://doi.org/10.4274/tnd.2021.06706

APA	Ozkan S, Erer S, Elibol B, Özkaynak S, çakmur r, Akbostanci M, Hanagasi H, DOGU O (2021). Parkinson Hastalığı Tedavisinde Apomorfin. Türk Nöroloji Dergisi, 27(4), 358 - 365. 10.4274/tnd.2021.06706
Chicago	Ozkan Serhat,Erer Sevda,Elibol Bulent,Özkaynak Sehür Sibel,çakmur raif,Akbostanci Muhittin Cenk,Hanagasi Hasmet,DOGU OKAN Parkinson Hastalığı Tedavisinde Apomorfin. Türk Nöroloji Dergisi 27, no.4 (2021): 358 - 365. 10.4274/tnd.2021.06706
MLA	Ozkan Serhat,Erer Sevda,Elibol Bulent,Özkaynak Sehür Sibel,çakmur raif,Akbostanci Muhittin Cenk,Hanagasi Hasmet,DOGU OKAN Parkinson Hastalığı Tedavisinde Apomorfin. Türk Nöroloji Dergisi, vol.27, no.4, 2021, ss.358 - 365. 10.4274/tnd.2021.06706
AMA	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O Parkinson Hastalığı Tedavisinde Apomorfin. Türk Nöroloji Dergisi. 2021; 27(4): 358 - 365. 10.4274/tnd.2021.06706
Vancouver	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O Parkinson Hastalığı Tedavisinde Apomorfin. Türk Nöroloji Dergisi. 2021; 27(4): 358 - 365. 10.4274/tnd.2021.06706
IEEE	Ozkan S,Erer S,Elibol B,Özkaynak S,çakmur r,Akbostanci M,Hanagasi H,DOGU O "Parkinson Hastalığı Tedavisinde Apomorfin." Türk Nöroloji Dergisi, 27, ss.358 - 365, 2021. 10.4274/tnd.2021.06706
ISNAD	Ozkan, Serhat vd. "Parkinson Hastalığı Tedavisinde Apomorfin". Türk Nöroloji Dergisi 27/4 (2021), 358-365. https://doi.org/10.4274/tnd.2021.06706